Last reviewed · How we verify
NCT05176132: SDOI
South Danish Obesity Initiative, Screening for Unrecognized Obesity Related Disease
trial testing Life style intervention (dietician+ physiotherapist) in Obesity in 2,700 participants. Currently enrolling.
1 September 2025
Quick facts
| Lead sponsor | Claus Bogh Juhl |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,700 |
| Start date | 1 September 2020 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 September 2030 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Life style intervention (dietician+ physiotherapist)
- Self management
- No intervention
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
Claus Bogh Juhl
Who can join
Adults 18 to 60, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
People with BMI \>30 kg/m2 will be included in at population-based cohort. Additionally, one control group with BMI 18.5-25 kg/m2 and one control group with BMI 25-30 kg/m2 will be included. All participants with age 18 and 60 years. To evaluate health status participants will be screened by for undetected obesity-related diseases (hypertension, diabetes, dyslipidemia, sleep apnea, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease, EKG-abnormalities, polycystic ovary syndrome (PCOS), and joint pain and for quality of life at baseline, 1 year, and 5 years. Additionally, anthropometric measurements are collected and a biobank is established for future research studies. People with obesity related disease will be offered participation in a 12 month personalized lifestyle intervention program aimed at improvement of health and self-perception. The collected data will be used to detect the prevalence for obesity-related disease to identify predictors for future obesity related disease and to evaluate the effect of a lifestyle intervention on health and quality of life.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prevalence of Obesity-Related Disease in a Danish Population - The Results of an Algorithm-Based Screening Program.
Juhl CB, Bladbjerg EM, Gram B, Knudsen T, et al · · 2024 · cited 4× · PMID 38910914 · DOI 10.2147/dmso.s456028
Verify or expand the search:
- PubMed search for NCT05176132
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Claus Bogh Juhl trials
Trials by the same sponsor.
- NCT03466021 — Effects of Liraglutide in Chronic Obstructive Pulmonary Disease · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05176132 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Claus Bogh Juhl
- Last refreshed: 19 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05176132.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing